Please login to the form below

Not currently logged in
Email:
Password:

Alder Biopharmaceuticals

This page shows the latest Alder Biopharmaceuticals news and features for those working in and with pharma, biotech and healthcare.

Novartis says migraine prevention drug clears phase III trial

Novartis says migraine prevention drug clears phase III trial

Novartis and Amgen are in a race withand Alder Biopharmaceuticals to bring the first CGRP-blocking drug to market.

Latest news

More from news
Approximately 1 fully matching, plus 6 partially matching documents found.

Latest Intelligence

  • Deal Watch January 2018

    Licence. 217. Teva Pharmaceuticals/ Alder Biopharmaceuticals. Patents covering anti-calcitonin gene-related peptide (CGRP) antibodies and methods - eptinezumab (p3). † ... Teva/Alder Biopharmaceuticals patent settlement. We have featured Teva in Deal

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
M&F Health

M&F Health is a full service communications agency, dedicated to the health and wellbeing sector. We are an independent amongst...

Latest intelligence

image 1
Redefining communications excellence
How to be heard in today’s multichannel, multistakeholder, multimedia world...
AZ Campus
AstraZeneca: building a new ‘open innovation’ pharma company
The construction of its new HQ has suffered some serious delays, but new R&D and commercial success are lifting AstraZeneca’s prospects...
Erik Nordkamp
In conversation with Pfizer’s Erik Nordkamp
Pfizer’s UK general manager talks to PME about the NHS at 70, the potential of pharma partnerships and some lessons from Europe...

Infographics